Olopatadine

Olopatadine
Clinical data
Trade namesPatanol, Pataday, Opatanol
AHFS/Drugs.comMonograph
MedlinePlusa602025
License data
Pregnancy
category
  • AU: B1
Routes of
administration		Eye drops, nasal spray
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only / OTC[1]
  • EU: Rx-only
Pharmacokinetic data
Elimination half-life3 hours
Identifiers
  • {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-
    dihydrodibenzo[b,e]oxepin-2-yl}acetic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H23NO3
Molar mass337.419 g·mol−1
3D model (JSmol)
  • O=C(O)Cc2ccc1OCc3c(C(\c1c2)=C\CCN(C)C)cccc3
  • InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8- checkY
  • Key:JBIMVDZLSHOPLA-LSCVHKIXSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Olopatadine, sold under the brand name Patanol among others, is an antihistamine medication used to decrease the symptoms of allergic conjunctivitis and allergic rhinitis (hay fever).[2] It is used as eye drops or as a nasal spray.[2] The eye drops generally result in an improvement within half an hour.[2]

Common side effects include headache, sore throat, eye discomfort, or changes in perception of taste.[3][2] More significant side effects may include sleepiness.[2] It is unclear if use during pregnancy or breastfeeding is safe.[4] It is an antihistamine and mast cell stabilizer.[5][2]

Olopatadine was patented in 1986 and came into medical use in 1997.[6] It is available as a generic medication.[2] In 2021, it was the 263rd most commonly prescribed medication in the United States, with more than 1 million prescriptions.[7][8]

  1. ^ "FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process". U.S. Food and Drug Administration (FDA). 14 February 2020. Archived from the original on 15 February 2020. Retrieved 14 February 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  2. ^ a b c d e f g "Olopatadine Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 27 March 2019. Retrieved 26 March 2019.
  3. ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1126. ISBN 9780857113382.
  4. ^ "Olopatadine ophthalmic Use During Pregnancy". Drugs.com. Archived from the original on 26 March 2019. Retrieved 26 March 2019.
  5. ^ Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A (June 2015). "Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis" (PDF). The Cochrane Database of Systematic Reviews. 2015 (6): CD009566. doi:10.1002/14651858.CD009566.pub2. hdl:2164/6048. PMC 10616535. PMID 26028608. Archived from the original on 28 August 2021. Retrieved 24 September 2019.
  6. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 549. ISBN 9783527607495. Archived from the original on 10 January 2023. Retrieved 20 September 2020.
  7. ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  8. ^ "Olopatadine - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 14 January 2024.